Literature DB >> 30172640

Nationwide comparative study of synchronous and metachronous spine metastasis in the adult Korean population.

Seil Sohn1, Chun Kee Chung2, Jin Hyung Jung3, Kyung Chul Lee1, Jinhee Kim4, Ung-Kyu Chang5, Moon Jun Sohn6, Sung Hwan Kim7.   

Abstract

This nationwide study of the adult Korean population aimed to compare the survival period between synchronous and metachronous group and to determine recent treatment trends in newly diagnosed spine metastasis patients. Data were extracted from the Korean Health Insurance Review and Assessment Service database. Patients in this study were newly diagnosed with metastatic spine tumors between July 1, 2011 and June 31, 2014. The metachronous group was defined when the primary tumor was diagnosed prior to the diagnosis of spine metastasis, otherwise patients were considered to be the part of the synchronous group. The survival period was calculated from the date of first diagnosis of spine metastasis. In a multivariate analysis, patients in the synchronous group survived significantly longer than those in the metachronous group (P < 0.0001). Median overall survival periods were 273.6 days for the metachronous group and 541.4 days for the synchronous group. Conventional radiation therapy (RT) was the most common treatment modality for metastatic spine tumors, whereas surgery combined with RT was a steadily increasing treatment modality during the study period. Synchronous spine metastasis patients survive significantly longer than metachronous patients. Surgery combined with RT is a recently increasing trend among spine metastasis treatments.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Epidemiology; Neoplasm metastasis; Neoplasms; Population; Spine

Mesh:

Year:  2018        PMID: 30172640     DOI: 10.1016/j.jocn.2018.08.048

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  1 in total

1.  Synchronous bone metastasis in lung cancer: retrospective study of a single center of 15,716 patients from Tianjin, China.

Authors:  Xu Guo; Wenjuan Ma; Haixiao Wu; Yao Xu; Dezheng Wang; Shuang Zhang; Zheng Liu; Vladimir P Chekhonin; Karl Peltzer; Jin Zhang; Xin Wang; Chao Zhang
Journal:  BMC Cancer       Date:  2021-05-26       Impact factor: 4.430

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.